12 July 2024: Aker BioMarine ASA ("Aker BioMarine" or "the company") announced
on 3 July a transaction to sell the Feed Ingredients business. The segment will
from the second quarter 2024 be a discontinued segment as it is classified as
held for sale. 

Highlights second quarter 2024:
- Subsequent event: Announced to sell the Feed Ingredients business for an
Enterprise Value of USD 590 million 
- Financials including discontinued operations line by line:  
   * Revenues of USD 94.0 million (up 6% YoY) 
   * Adjusted EBITDA of USD 29.0 million (up 35% YoY)
- Financials from continued operations
   * Revenues of USD 49.2 million (up 4% YoY)
   * Adjusted EBITDA of USD 6.7 million (down 21% YoY)
- Revenue growth YoY in HHI segment of 22%, margin impacted by customer mix and
high share of lower margin products PL+, Algae oil and QHP
- Revenue growth YoY in Feed Ingredients of 25% including Nutra, good
development in underlying margin
- Krill offshore production of 20,091 MT (up 13% YoY)
- Inventory build down at retailers impacted Lang sales, sales out of store
(POS) remains strong at 7% growth YoY for 1H 2024

"Following the Feed Ingredients transaction, Aker BioMarine will focus on human
nutrition, particularly the large and growing Omega-3 market. We aim to grow by
increasing our market share and expanding our product categories through
innovation. In parallel, we will continue to explore how we can drive
shareholder value by enabling potential partnerships and transactions for each
of the remaining business units," said Matts Johansen, CEO of Aker BioMarine.

Human Health Ingredients delivered solid revenue growth of 22%, with revenues
from krill oil equivalent products up 7% year-over-year (YoY). This revenue
growth is driven by continued strong development across most regions. Margins
for the quarter were impacted by customer mix in Superba and a high share of
lower-margin products such as PL+, Algae Oil, and QHP.

Consumer Health Products delivered lower revenues on a stable gross margin,
resulting in lower EBITDA on a relatively fixed SG&A base. Through the first
half of 2024, sales of Lang products out of store at retailers (POS) increased
by 7% YoY, while Lang revenues declined. This indicates that retailers have been
reducing inventory levels, while the underlying market for our private label
products remains strong.

Feed Ingredients delivered good results, with both higher revenues and improved
underlying margins compared to last year. This was driven by price growth of
Qrill Aqua and a higher share of high-margin products like Qrill Pet and Nutra.
Offshore production has also been robust, with Q2 and year-to-date (YTD)
production up 13% and 10% YoY respectively. From Q2 2024, this segment is
classified as held for sale and discontinued.

At 09:00 CET today, the management hosts a webcast. Following the presentation,
there will be a Q&A session, where written questions can be submitted to
ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that
is available at www.akerbiomarine.com/investor. 

A replay of the presentation and Q&A session material will be made available
soon after the presentation at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.